UCL 1684 (dibromide)

• UNSPSC Description:

  UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of INa. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness[1][2][3].

• Target Antigen:

  Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ucl-1684-dibromide.html

• Purity:

  98.07

• Solubility:

  DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  C12=[N+](CC3=CC(C[N+]4=CC=C(NCC5=CC=C(C=C5)CN6)C7=CC=CC=C47)=CC=C3)C=CC6=C1C=CC=C2.[Br-].[Br-]

• Molecular Weight:

  654.44

• References & Citations:

  [1]Burashnikov A, et al. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020;76(2):164-172.|[2]Rosa JC, et al. Bis-quinolinium cyclophanes: 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)- diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca(2+)-activated K+ channel. J Med Chem. 1998;41(1):2-5.|[3]Diness JG, et al. Effects on atrial fibrillation in aged hypertensive rats by Ca(2+)-activated K(+) channel inhibition. Hypertension. 2011;57(6):1129-1135.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  199934-16-2